China Pharma Holdings Inc Market Cap ($2.48 Million)
Market Cap & Net Worth: China Pharma Holdings Inc (CPHI)
China Pharma Holdings Inc market cap. China Pharma Holdings Inc (NYSE MKT:CPHI) has a market capitalization of $2.48 Million ($2.48 Million) as of October 31, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #29790 globally and #6088 in its home market, demonstrating a -38.71% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying China Pharma Holdings Inc's stock price $0.76 by its total outstanding shares 3262002 (3.26 Million).
China Pharma Holdings Inc Market Cap History (2015–2026)
China Pharma Holdings Inc market cap history from 2015 to 2026. Data shows change from $25.59 Million to $2.48 Million (-21.21% CAGR). Check China Pharma Holdings Inc (CPHI) stock price for real-time trading data and today's change.
China Pharma Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how China Pharma Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see China Pharma Holdings Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.17x
China Pharma Holdings Inc's market cap is 0.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $25.59 Million | $20.35 Million | -$15.41 Million | 1.26x | N/A |
| 2016 | $42.41 Million | $15.57 Million | -$9.18 Million | 2.72x | N/A |
| 2017 | $28.64 Million | $13.21 Million | -$19.28 Million | 2.17x | N/A |
| 2018 | $41.98 Million | $12.33 Million | -$10.75 Million | 3.40x | N/A |
| 2019 | $38.62 Million | $10.92 Million | -$20.70 Million | 3.54x | N/A |
| 2020 | $72.71 Million | $10.87 Million | -$2.87 Million | 6.69x | N/A |
| 2021 | $78.71 Million | $9.64 Million | -$3.40 Million | 8.16x | N/A |
| 2022 | $15.64 Million | $8.10 Million | -$3.97 Million | 1.93x | N/A |
| 2023 | $1.97 Million | $7.01 Million | -$3.08 Million | 0.28x | N/A |
| 2024 | $758.42K | $4.53 Million | -$4.74 Million | 0.17x | N/A |
Competitor Companies of CPHI by Market Capitalization
Companies near China Pharma Holdings Inc in the global market cap rankings as of October 31, 2026. See CPHI equity to assets ratio to understand what proportion of total assets are financed by equity.
Key companies related to China Pharma Holdings Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #515 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #600 globally with a market cap of $45.38 Billion USD ( CN¥310.15 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #626 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #515 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $45.98 |
| #600 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.38 Billion | CN¥48.62 |
| #626 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €17.90 |
Market Capitalization of China Pharma Holdings Inc (2015–2026)
Market capitalization of China Pharma Holdings Inc from 2015 to today. Between 2015 and today, China Pharma Holdings Inc's market cap moved from $25.59 Million to $ 2.48 Million, with a yearly change of -21.21%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.48 Million | -37.19% |
| 2025 | $3.95 Million | +420.43% |
| 2024 | $758.42K | -61.57% |
| 2023 | $1.97 Million | -87.38% |
| 2022 | $15.64 Million | -80.13% |
| 2021 | $78.71 Million | +8.25% |
| 2020 | $72.71 Million | +88.26% |
| 2019 | $38.62 Million | -8.00% |
| 2018 | $41.98 Million | +46.58% |
| 2017 | $28.64 Million | -32.46% |
| 2016 | $42.41 Million | +65.71% |
| 2015 | $25.59 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of China Pharma Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.48 Million USD |
| MoneyControl | $2.48 Million USD |
| MarketWatch | $2.48 Million USD |
| marketcap.company | $2.48 Million USD |
| Reuters | $2.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About China Pharma Holdings Inc
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin inje… Read more